Publications by authors named "Xingya Li"

Claim this Profile
F
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial.
Shun Lu, Jie Wang, Yan Yu, Xinmin Yu, Yanping Hu, Liao Wangjun, Xingya Li, Yuepeng Liu, Weidong Li

Oncol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.
Jia Zhong, Lin Wu, Zhengbo Song, Nianzeng Xing, Jiujie Cui, Xingya Li, Liang Chen, Tianshu Liu, Caigang Liu, Yong Li, Rongrui Liu, Zhifei Lin

Cancer Cell· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.
Jian Li, Zhenghang Wang, Jing Huang, Yi Ba, Baoshan Cao, Wenhua Li, Liangjun Zhu, Zhihua Li, Yongsheng Li, Xingya Li, Xianli Yin, Xinjun Liang, Xiaoyan Li, Zhen Li, Lian Liu, Rong Liang, Yuli Ding, Lin Shen

Lancet Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
Yi-Long Wu, Yu Yao, Jin-Ji Yang, Lin Wu, Wei Zhang, Xing-Ya Li, Si-Yang Maggie Liu

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.
Shaodong Hong, Qiming Wang, Ying Cheng, Yongzhong Luo, Xiujuan Qu, Xingya Li, Lin Wu, Anwen Liu, Li Zhang

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.
Jian Li, Ting Deng, Yanhong Gu, Antonio Calles Blanco, Zhihua Li, Lin Wu, Xingya Li, Yongsheng Li, Lian Liu, Ligang Xing, Julia Martínez-Pérez, Yuli Ding, Sumei Liu, Xinghu Liu, Lin Shen

Cancer Commun (Lond)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Zhiwei Chen, Fang Yang, Zhou Jiang, Longhua Sun, Lin Wu, Xingya Li, Ying Liu, Pingli Wang, Jie Li, Shuliang Guo, Juan Li, Xuewen Liu, Zhengguo Li, Dairong Li, Jie Li, Hualin Chen, Wenting Li, Baiyong Li

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Porous organic cage mixed matrix membranes for efficient enantioseparation.
Yifan Li, Zheng Liu, Daojiang Zhu, Yuan Xia, Bin Wu, Xingya Li

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecirasib plus sitneprotafib in patients with KRAS-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.
Jia Zhong, Jun Zhao, Jianchun Duan, Jian Fang, Kailun Fei, Xiaoyan Li, Zhe Liu, Li Zhang, Xingya Li, Lin Wu, Ligang Xing, Lian Liu, Yuli Ding

Lancet Respir Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, Yun Fan, Dongqing Lv, Meili Sun, Laurent Greillier, Julien Mazieres, Enriqueta Felip, Xingya Li, François Ghiringhelli, Bruna Pellini, Geoffrey Liu, Li Zheng

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, -Mutated Advanced NSCLC.
Wenfeng Fang, Lin Wu, Xiangjiao Meng, Yu Yao, Wei Zuo, Xingya Li, Kai Li, Zhentian Liu, Liyan Jiang, Li Zhang

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Zhuqing Liu, Zhicai Lin, Linlin Li, Jiaguo Li, Tao Liu, Yi Liu, Lijie Rong

Adv Sci (Weinh)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.
Dan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo, Wen-Wen Huang, Xin-Jun Liang, Hong-Li Li, Xing-Ya Li, Zhou Li, Lian Liu, He-Li Liu, Ai-Li Suo, Yong-Qiang Li

Nat Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multifunctional intercalants create stable subnanochannels in MoS membranes for wastewater treatment.
Hao Zhang, Ming Yong, Ting Hu, Yuan Kang, Zhuyuan Wang, Xuefeng Li, Lijun Guo, Zhikao Li, Xingya Li

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with exon 14 skipping mutated non-small cell lung cancer.
Shun Lu, Yongfeng Yu, Jianya Zhou, Xingya Li, Koichi Goto, Ling Wu, Lu Li, Xiaoling Li, Li Zhang, Fugen Li

Transl Lung Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Xingya Li, Jing Li, Chen Ling

Cancer Commun (Lond)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
Caicun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Jiwei Liu, Yunpeng Liu, Xingya Li, Jingzhang Li, Changli Wang, Chunling Liu, Lin Li, Li Liang, Man Li

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
Shen Zhao, Ying Cheng, Qiming Wang, Xingya Li, Jun Liao, Yongsheng Li, Yaling Li, Jin Li, Li Zhang

Nat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).
Jianming Xu, Lin Shen, Jie Li, Zhiwei Zhou, Chunmei Bai, Zhiping Li, Yihebali Chi, Enxiao Li, Xianglin Yuan, Tianshu Liu, Xingya Li

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab tirumotecan versus docetaxel for previously treated -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial.
Wenfeng Fang, Xingya Li, Qiming Wang, Xiangjiao Meng, Wei Zheng, Li Zhang

BMJ· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, Pamela N Munster, Yanhong Deng, Xingya Li, Yaolin Wang, Ling Zhang

Signal Transduct Target Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.
Yuankai Shi, Yanzhen Guo, Xingya Li, Lin Wu, Zhaohong Chen, Meili Sun, Liangming Zhang, Yingcheng Lin, Lijun Wang, Meiling Wen, Shuliang Guo, Manxiang Li, Wen Li, Zheng Liu

Lancet Respir Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.
Ziming Li, Yan Wang, Yuping Sun, Linlin Wang, Xingya Li, Donglin Wang, Wenhua Liang, You Li

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu, Baogang Liu, Jie Li, Bolin Chen, Jinliang Wang, Ligong Nie, Gaofeng Li, Xingya Li, Yu Lin, Xuewen Liu, Baiyong Li

Lancet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.
Dan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, Yanqiu Zhao, Yehui Shi, Jie Lin, Yunpeng Liu, Caigang Liu, Manxiang Li, Meili Sun, Xingya Li, Xianglin Yuan, Yalun Li, Shengqing Li, Dongying Liu, Liping Tan

Signal Transduct Target Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis